---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-187733"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:11:16.608672+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst settles Lupin patent litigation; generic FIRDAPSE launch no earlier than Feb 2035

## Summary
- Lupin granted license to market generic FIRDAPSE beginning February 25, 2035, if FDA-approved.
- All ongoing patent litigation between Catalyst/SERB and Lupin in New Jersey terminated.
- Prior settlements with Teva and Inventia for FIRDAPSE generics already in place.
- Pending patent litigation against Hetero for FIRDAPSE's Orange Book-listed patents continues.
- Settlement will be submitted to FTC and DOJ for review as required.

## SEC filing metadata
- accession: 0001193125-25-187733
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/0001193125-25-187733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/d915025d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-187733
- JSON: https://secwatch.observer/filing/0001193125-25-187733.json
- Plain text: https://secwatch.observer/filing/0001193125-25-187733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.